Literature DB >> 18312284

Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study.

Helen M Conaglen1, John V Conaglen2.   

Abstract

INTRODUCTION: Several preference studies comparing a short-acting with a longer-acting phosphodiesterase type 5 inhibitor have been conducted in men. Most men in those studies preferred tadalafil rather than sildenafil, and recent post hoc analysis of one study described several factors associated with men's treatment preference. No prospective studies have investigated the woman partners' preferences. AIM: To investigate the treatment preference of women who were partners of men using oral medications for erectile dysfunction (ED) in a single-center open-label crossover study.
METHODS: One hundred heterosexual couples in stable relationships, with male partners having ED based on the erectile function subscale of the International Index of Erectile Function, were randomly assigned to receive sildenafil or tadalafil for a 12-week phase, followed by another 12-week period using the alternate drug. Male and female participants completed sexual event diaries during both study phases, and the female participants were interviewed at baseline, midpoint, and end of study. MAIN OUTCOME MEASURES: Primary outcome data were the women's final interviews during which they were asked which drug they preferred and their reasons for that preference.
RESULTS: A total of 79.2% of the women preferred their partners' use of tadalafil, while 15.6% preferred sildenafil. Preference was not affected by age or treatment order randomization. Women preferring tadalafil reported feeling more relaxed, experiencing less pressure, and enjoying a more natural or spontaneous sexual experience as reasons for their choice. Mean number of tablets used, events recorded, events per week, and days between events were not significantly different during each study phase.
CONCLUSION: Women's preferences were similar to men when using these two drugs. While the women's reasons for preferring tadalafil emphasized relaxed, satisfying, longer-lasting sexual experiences, those preferring sildenafil focused on satisfaction and drug effectiveness for their partner.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18312284     DOI: 10.1111/j.1743-6109.2008.00774.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  13 in total

Review 1.  Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.

Authors:  Mary Lee; Roohollah Sharifi
Journal:  Drugs Aging       Date:  2018-03       Impact factor: 3.923

2.  AUTHOR REPLY: The nuances of GRADE.

Authors:  Trustin Domes; Borna Tadayon Najafabadi; Matthew Roberts; Jeffrey Campbell; Ryan Flannigan; Phil Bach; Premal Patel; Gavin Langille; Yonah Krakowsky; Philippe D Violette
Journal:  Can Urol Assoc J       Date:  2021-12       Impact factor: 1.862

3.  Canadian Urological Association guideline: Erectile dysfunction.

Authors:  Trustin Domes; Borna Tadayon Najafabadi; Matthew Roberts; Jeffrey Campbell; Ryan Flannigan; Phil Bach; Premal Patel; Gavin Langille; Yonah Krakowsky; Philippe D Violette
Journal:  Can Urol Assoc J       Date:  2021-10       Impact factor: 1.862

Review 4.  The role of the sexual partner in managing erectile dysfunction.

Authors:  Hongjun Li; Tiejun Gao; Run Wang
Journal:  Nat Rev Urol       Date:  2016-02-02       Impact factor: 14.432

Review 5.  A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy.

Authors:  Samuel L Washington; Alan W Shindel
Journal:  Drug Des Devel Ther       Date:  2010-09-07       Impact factor: 4.162

6.  An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.

Authors:  Wen-Jun Bai; Hong-Jun Li; Yu-Tian Dai; Xue-You He; Yi-Ran Huang; Ji-Hong Liu; Sebastian Sorsaburu; Chen Ji; Jian-Jun Jin; Xiao-Feng Wang
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

7.  Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors.

Authors:  Giovanni Corona; Carlo B Giorda; Domenico Cucinotta; Piero Guida; Elisa Nada
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

8.  Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives.

Authors:  Pierre Costa; Thierry Grivel; Naji Gehchan
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

9.  Tadalafil in the treatment of erectile dysfunction.

Authors:  Robert M Coward; Culley C Carson
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

10.  An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction.

Authors:  Hong-Jun Li; Wen-Jun Bai; Yu-Tian Dai; Wen-Ping Xu; Chia-Ning Wang; Han-Zhong Li
Journal:  Asian J Androl       Date:  2016 Sep-Oct       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.